Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Is Another Heparin Crisis Looming? Congress Raises Alarm, Demands US FDA Briefing

Executive Summary

The FDA must explain how it will prevent heparin adulteration as a virus kills pigs in China again.

You may also be interested in...



FDA CDER Compliance Office Answered Pandemic With Fewer Inspections, Greater Discretion

Fewer inspections but more warning letters, import alerts and drug-shortage discretions were seen as office sought to ameliorate COVID-19 impacts.

The Quality Lowdown: Import Alert Update

Crude heparin supplier Yibin Lihao headlines list of facilities in 12 countries added to the US FDA’s drug GMP import alert.

China Heparin Quality Under Pressure Again, Congress Warns FDA

US House committee requests FDA commissioner to provide a contingency response plan should pressures on China's heparin supply chain trigger more of the economically motivated adulteration that killed scores of US patients in 2008.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS140619

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel